Tear Replacement Therapy in Medical Support of Patients after Femto-LASIK Keratorefractive Surgery
Open Access
- 23 June 2020
- journal article
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 17 (2), 274-280
- https://doi.org/10.18008/1816-5095-2020-2-274-280
Abstract
Purpose— to analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the FemtoLASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition.Patients andmethods.The study included 25 patients (50 eyes) who underwent a keratorefractive surgery (Femto-LASIK) and were prescribed instillations of artificial tear drops HILOPARIN-COMOD®. To analyze the effectiveness of artificial tear drops HYLOPARIN-COMOD® in the complex medical support of the Femto-LASIK operation based on monitoring of clinical, functional and morphometric indicators of the eye surface’s condition: UCVA, BCVA, Schirmer’s II test, tear break-up time (Norn’s test), OCT pachymetry of the cornea and corneal flap. The treatment effectiveness was evaluated at 1 day, 1 week, 1 and 3 months after the surgery.Results.As a result of the treatment, the following refractive data were obtained: UCVA increased from 0.09 ± 0.02 to 0.94 ± 0.07 on the first day after surgery and to 0.96 ± 0.04 and 0.99 ± 0.07 to 1 and 3 months of follow-up, BCVA respectively, from 0.97 ± 0.04 to 0.94 ± 0.07, 0.97 ± 0.07 and 0.99 ± 0.07 after surgery. A faster restoration of the cornea and corneal valve was revealed, as evidenced by a decrease in their thickness already in the 1st week after surgery in comparison with the control group, where were more pronounced changes occur only by the 1st and 3rd month of observation (p ≤ 0.05). There was a significant increase in the basal secretion of the lacrimal gland (Schirmer’s II test) from 10.16 ± 1.33 to 11.66 ± 1.13 and 12.88 ± 0.96 µm by 1 and 3 months after surgical treatment, respectively (p ≤ 0.05). The Norn’s test increased from 10.89 ± 1.94 to 12.78 ± 1.59 and 13.83 ± 0.5 s to 1 and 3 months of treatment, respectively (p ≤ 0.05).Conclusion.The effectiveness of the HILOPARIN-COMOD® use in the correction of the dry eye syndrome after keratorefractive operations has been proven. The obtained results clearly demonstrate that the HILOPARIN-COMOD® preparation enhances not only the stability of the tear film, but also the restoration of the OCT morphometric parameters of the thickness of the cornea and corneal flap.Keywords
This publication has 10 references indexed in Scilit:
- Guidelines for the Management of Patients with Herpetic Keratitis/Keratouveitis in the Long Term: from Problem to SolutionOphthalmology in Russia, 2019
- New Properties of the Heparin-Containing Drug in vitro (Potential Antiviral and Anti-Inflammatory Effects)Ophthalmology in Russia, 2018
- Effect of a hyaluronic acid and carboxymethylcellulose ophthalmic solution on ocular comfort and tear-film instability after cataract surgeryJournal of Cataract & Refractive Surgery, 2015
- The experience of “Hyloparin” use in clinical practiceOphthalmology Reports, 2014
- TRPV1 Activation Is Required for Hypertonicity-Stimulated Inflammatory Cytokine Release in Human Corneal Epithelial CellsInvestigative Ophthalmology & Visual Science, 2011
- RA: overview of recommended diagnosis and drug treatmentPrescriber, 2010
- Postrefractive surgery dry eyeCurrent Opinion in Opthalmology, 2008
- The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007)The Ocular Surface, 2007
- Un nouveau schéma pour mieux comprendre les maladies de la surface oculaireJournal Français d'Ophtalmologie, 2007
- Excimer laser photorefractive keratectomy for patients with contact lens intolerance caused by dry eye.British Journal of Ophthalmology, 1996